Ergosterol Biosynthesis Inhibitors Become Fungicidal when Combined with Calcineurin Inhibitors against Candida albicans , Candida glabrata , and Candida krusei
Open Access
- 1 March 2003
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 47 (3) , 956-964
- https://doi.org/10.1128/aac.47.3.956-964.2003
Abstract
Azoles target the ergosterol biosynthetic enzyme lanosterol 14α-demethylase and are a widely applied class of antifungal agents because of their broad therapeutic window, wide spectrum of activity, and low toxicity. Unfortunately, azoles are generally fungistatic and resistance to fluconazole is emerging in several fungal pathogens. We recently established that the protein phosphatase calcineurin allows survival of Candida albicans during the membrane stress exerted by azoles. The calcineurin inhibitors cyclosporine A (CsA) and tacrolimus (FK506) are dramatically synergistic with azoles, resulting in potent fungicidal activity, and mutant strains lacking calcineurin are markedly hypersensitive to azoles. Here we establish that drugs targeting other enzymes in the ergosterol biosynthetic pathway (terbinafine and fenpropimorph) also exhibit dramatic synergistic antifungal activity against wild-type C. albicans when used in conjunction with CsA and FK506. Similarly, C. albicans mutant strains lacking calcineurin B are markedly hypersensitive to terbinafine and fenpropimorph. The FK506 binding protein FKBP12 is required for FK506 synergism with ergosterol biosynthesis inhibitors, and a calcineurin mutation that confers FK506 resistance abolishes drug synergism. Additionally, we provide evidence of drug synergy between the nonimmunosuppressive FK506 analog L-685,818 and fenpropimorph or terbinafine against wild-type C. albicans. These drug combinations also exert synergistic effects against two other Candida species, C. glabrata and C. krusei, which are known for intrinsic or rapidly acquired resistance to azoles. These studies demonstrate that the activity of non-azole antifungal agents that target ergosterol biosynthesis can be enhanced by inhibition of the calcineurin signaling pathway, extending their spectrum of action and providing an alternative approach by which to overcome antifungal drug resistance.Keywords
This publication has 49 references indexed in Scilit:
- Candida albicans Sterol C-14 Reductase, Encoded by the ERG24 Gene, as a Potential Antifungal Target SiteAntimicrobial Agents and Chemotherapy, 2002
- Calcineurin is essential for survival during membrane stress in Candida albicansThe EMBO Journal, 2002
- Cryptococcus neoformansInfection in Organ Transplant Recipients: Variables Influencing Clinical Characteristics and OutcomeEmerging Infectious Diseases, 2001
- Cryptococcus neoformansInfection in Organ Transplant Recipients: Variables Influencing Clinical Characteristics and OutcomeEmerging Infectious Diseases, 2001
- When to Suspect Fungal Infection in Neonates: A Clinical Comparison ofCandida albicansandCandida parapsilosisFungemia With Coagulase-Negative Staphylococcal BacteremiaPediatrics, 2000
- National Surveillance of Nosocomial Blood Stream Infection Due to Species of Candida Other than Candida albicans: Frequency of Occurrence and Antifungal Susceptibility in the SCOPE ProgramDiagnostic Microbiology and Infectious Disease, 1998
- Selection ofCandida glabrata strains with reduced susceptibility to azoles in four liver transplant patients with invasive candidiasisEuropean Journal of Clinical Microbiology & Infectious Diseases, 1997
- Crystal structures of human calcineurin and the human FKBP12–FK506–calcineurin complexNature, 1995
- X-ray structure of calcineurin inhibited by the immunophilin-immunosuppressant FKBP12-FK506 complexCell, 1995
- The gene encoding squalene epoxidase from Saccharomyces cerevisiae: cloning and characterizationGene, 1991